<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/01/shutterstock_2170801815-430x241.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/01/shutterstock_2170801815-430x241.jpg"/></p>
<p>Seamless 的平台可以在基因组中进行大规模但精确的 DNA 编辑，从而能够治疗广泛的疾病。isak55 via Shutterstock.com。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2024/04/Cytiva-PT-image-1024x87.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2024/04/Cytiva-PT-image-1024x87.png"/></p>
<p>在继续增强其基因治疗管线的举措中，礼来与基因编辑公司 Seamless Therapeutics 签署了一项全球研究合作和许可协议。</p>
<p>该合作将使两家公司开发和商业化针对听力损失指征的可编程重组酶基础治疗。作为使用 Seamless 重组酶平台的交换，礼来将向该生物技术公司支付超过 11.2 亿美元的预付款和研发资金。里程碑付款和任何获批药物的额外版税的具体细节未披露。</p>
<p>总部位于德国的 Seamless 于 2023 年成立，利用可编程重组酶来解决遗传疾病。重组酶是催化特定位点 DNA 重排的专门酶，包括切除、插入和转位。这些酶在科学研究中已使用数十年，但直到现在才被用于商业化治疗的潜力。该生物技术公司表示，其平台可以在基因组中进行大规模但精确的 DNA 编辑，从而能够治疗广泛的疾病。</p>
<p>在与礼来的交易后，Seamless 将设计和编程针对特定基因突变的位点特异性重组酶，以纠正与听力损失相关的突变。礼来将获得这些编程重组酶的独占许可，以推进临床前和临床药物开发及商业化。</p>
<p>Seamless 的首席执行官 Albert Seymour 表示：“我们期待与礼来的合作，朝着改善遗传性听力损失患者的结果这一共同目标努力。这是一个令人兴奋的机会，可以应用我们的技术为听力损失患者带来治疗，并继续通过我们的专有管线扩展可编程重组酶的治疗潜力。”</p>
<h2>礼来加大对基因治疗交易的投入</h2>
<p>与 Seamless 的合作标志着礼来最新的基因治疗承诺，尽管一些制药公司选择退出该领域。2025 年 5 月，这家制药公司花费 13 亿美元收购了韩国生物技术公司 Rznomics，该公司正在开发针对听力损失的 RNA 基础治疗。随后在 6 月，礼来以 13 亿美元收购了基因编辑合作伙伴 Verve Therapeutics。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/></p>
<p>GlobalData 战略情报</p>
<p>不要让政策变化让你措手不及。通过实时数据和专家分析保持主动。</p>
<p>由 GlobalData 提供</p>
<p>礼来在 2025 年 10 月收购了 Adverum，并在一个月后与 MeiraGTx 签署了一项 4.75 亿美元的许可协议——这两笔交易均涉及眼科基因治疗领域。</p>
<p>礼来已经有一个针对听力损失的基因治疗候选药物 AK-OTOF。在 2024 年发布的 I/II 期数据（NCT05572073）中，该疗法显示出能够恢复一名从出生就有听力损失的儿童的听力。</p>
<p>根据 GlobalData 的报告，细胞和基因治疗（CGT）风险投资活动在 B 轮阶段最为显著。</p>
<p>关于大型制药公司进行的 CGT 收购，GlobalData 的高级医疗研究员 Irena Maragkou 表示：“此类收购越来越趋向于基于治疗方式，并专注于平台、可扩展的制造系统和能够支持整个投资组合 CGT 扩展努力的专业能力。然而，大型制药公司仍然表现出愿意为一些晚期或临床验证的资产支付溢价，只要它们与长期战略目标和投资组合一致。”</p>
<p>除了细胞和基因治疗，礼来在 2026 年迄今为止在并购舞台上是最活跃的大型制药公司。1 月，该公司收购了炎症专科公司 Ventyx，交易金额为 12 亿美元，并与 Nimbus 签署了一项针对肥胖的研究协议，金额为 13 亿美元。</p>
<p><em>Pharmaceutical Technology 上的细胞与基因治疗报道由 Cytiva 支持。</em></p>
<p><em>编辑内容独立制作，并遵循_最高标准_的新闻诚信。主题赞助商不参与编辑内容的创作。</em></p>

<p>礼来与 Seamless Therapeutics 达成全球研究合作，承诺投资超过 11.2 亿美元用于开发针对听力损失的基因疗法。该合作将利用 Seamless 的重组酶平台来创建可编程治疗方案。这一举措是礼来增强其基因疗法管道的更广泛战略的一部分，此前该公司在该领域进行了多项收购。Seamless 将设计重组酶以修正与听力损失相关的基因突变，礼来将获得进一步开发和商业化的独家权利</p>

<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/01/shutterstock_2170801815-430x241.jpg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/01/shutterstock_2170801815-430x241.jpg"/></p>
<p>Seamless’ platform can perform large but precise DNA edits along the genome, enabling treatment across a broad range of diseases. isak55 via Shutterstock.com.</p>
<div class="lb-trans"><p>Seamless 的平台可以在基因组中进行大规模但精确的 DNA 编辑，从而能够治疗广泛的疾病。isak55 via Shutterstock.com。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2024/04/Cytiva-PT-image-1024x87.png" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2024/04/Cytiva-PT-image-1024x87.png"/></p>
<p>In a move that continues a recent bolstering of its gene therapy pipeline, Eli Lilly has signed a global research collaboration and licensing agreement with gene editing company Seamless Therapeutics.</p>
<div class="lb-trans"><p>在继续增强其基因治疗管线的举措中，礼来与基因编辑公司 Seamless Therapeutics 签署了一项全球研究合作和许可协议。</p>
</div><p>The partnership will see the two companies develop and commercialise programmable recombinase-based treatments targeting hearing loss indications. In exchange for using Seamless’ recombinase platform, Lilly will pay the biotech over $1.12bn in an upfront payment and R&amp;D funding. The exact breakdown of milestone payments and additional royalties on any approved drugs was not disclosed.</p>
<div class="lb-trans"><p>该合作将使两家公司开发和商业化针对听力损失指征的可编程重组酶基础治疗。作为使用 Seamless 重组酶平台的交换，礼来将向该生物技术公司支付超过 11.2 亿美元的预付款和研发资金。里程碑付款和任何获批药物的额外版税的具体细节未披露。</p>
</div><p>Germany-based Seamless, which launched in 2023, uses programmable recombinases to address genetic diseases. Recombinases are specialised enzymes that catalyse site-specific DNA rearrangements, including excision, insertion, and translocation. These enzymes have been used in scientific research for decades, but only now are they being harnessed for the potential of commercialised therapies. The biotech says its platform can perform large but precise DNA edits along the genome, enabling treatment across a broad range of diseases.</p>
<div class="lb-trans"><p>总部位于德国的 Seamless 于 2023 年成立，利用可编程重组酶来解决遗传疾病。重组酶是催化特定位点 DNA 重排的专门酶，包括切除、插入和转位。这些酶在科学研究中已使用数十年，但直到现在才被用于商业化治疗的潜力。该生物技术公司表示，其平台可以在基因组中进行大规模但精确的 DNA 编辑，从而能够治疗广泛的疾病。</p>
</div><p>Following the deal with Lilly, Seamless will design and programme site-specific recombinases directed to correct mutations in certain genes of interest related to hearing loss. Lilly will receive an exclusive license to the programmed recombinases to advance through preclinical and clinical drug development and commercialisation.</p>
<div class="lb-trans"><p>在与礼来的交易后，Seamless 将设计和编程针对特定基因突变的位点特异性重组酶，以纠正与听力损失相关的突变。礼来将获得这些编程重组酶的独占许可，以推进临床前和临床药物开发及商业化。</p>
</div><p>Albert Seymour, Seamless’s CEO, said: “We look forward to working with our partners at Lilly in our shared goal to transform the outcome for patients with genetic hearing loss. It’s an exciting opportunity to apply our technology to bring treatments to patients with hearing loss and continue to expand the therapeutic potential for programmable recombinases through our proprietary pipeline.”</p>
<div class="lb-trans"><p>Seamless 的首席执行官 Albert Seymour 表示：“我们期待与礼来的合作，朝着改善遗传性听力损失患者的结果这一共同目标努力。这是一个令人兴奋的机会，可以应用我们的技术为听力损失患者带来治疗，并继续通过我们的专有管线扩展可编程重组酶的治疗潜力。”</p>
</div><h2>Lilly doubles down on gene therapy deals</h2>
<div class="lb-trans"><h2>礼来加大对基因治疗交易的投入</h2>
</div><p>The collaboration with Seamless marks the latest gene therapy commitment by Lilly, despite some pharma companies opting to retreat from the sector. In May 2025, the drugmaker spent $1.3bn to acquire Rznomics, a South Korea-based biotech developing RNA-based therapies for hearing loss. Then in June, Lilly bought gene editing partner Verve Therapeutics for $1.3bn.</p>
<div class="lb-trans"><p>与 Seamless 的合作标志着礼来最新的基因治疗承诺，尽管一些制药公司选择退出该领域。2025 年 5 月，这家制药公司花费 13 亿美元收购了韩国生物技术公司 Rznomics，该公司正在开发针对听力损失的 RNA 基础治疗。随后在 6 月，礼来以 13 亿美元收购了基因编辑合作伙伴 Verve Therapeutics。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/></p>
<p>GlobalData Strategic Intelligence</p>
<div class="lb-trans"><p>GlobalData 战略情报</p>
</div><p>Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.</p>
<div class="lb-trans"><p>不要让政策变化让你措手不及。通过实时数据和专家分析保持主动。</p>
</div><p>By GlobalData</p>
<div class="lb-trans"><p>由 GlobalData 提供</p>
</div><p>Lilly bought Adverum in October 2025 and signed a $475m licensing deal with MeiraGTx a month later – both deals were in the ophthalmic gene therapy space.</p>
<div class="lb-trans"><p>礼来在 2025 年 10 月收购了 Adverum，并在一个月后与 MeiraGTx 签署了一项 4.75 亿美元的许可协议——这两笔交易均涉及眼科基因治疗领域。</p>
</div><p>Lilly already has one gene therapy candidate for hearing loss in the form of AK-OTOF. In Phase I/II data (NCT05572073) released in 2024, the therapy was shown to restore hearing in one child who had hearing loss from birth.</p>
<div class="lb-trans"><p>礼来已经有一个针对听力损失的基因治疗候选药物 AK-OTOF。在 2024 年发布的 I/II 期数据（NCT05572073）中，该疗法显示出能够恢复一名从出生就有听力损失的儿童的听力。</p>
</div><p>Cell and gene therapy (CGT) venture capital activity is most prominent in the Series B-stage, a report by GlobalData discovered.</p>
<div class="lb-trans"><p>根据 GlobalData 的报告，细胞和基因治疗（CGT）风险投资活动在 B 轮阶段最为显著。</p>
</div><p>Regarding CGT acquisitions made by big pharma, Irena Maragkou, senior healthcare researcher at GlobalData, says: “Such acquisitions are becoming increasingly modality-driven and focused on platforms, scalable manufacturing systems, and specialised capabilities that can support portfolio-wide CGT expansion efforts. However, big pharma continues to demonstrate willingness to pay a premium for some late-stage or clinically validated assets when they align with long-term strategic objectives and portfolios.”</p>
<div class="lb-trans"><p>关于大型制药公司进行的 CGT 收购，GlobalData 的高级医疗研究员 Irena Maragkou 表示：“此类收购越来越趋向于基于治疗方式，并专注于平台、可扩展的制造系统和能够支持整个投资组合 CGT 扩展努力的专业能力。然而，大型制药公司仍然表现出愿意为一些晚期或临床验证的资产支付溢价，只要它们与长期战略目标和投资组合一致。”</p>
</div><p>Beyond cell and gene therapies, Lilly has been the busiest big pharma company on the M&amp;A stage so far in 2026. In January, the company acquired inflammatory specialist Ventyx for $1.2bn and signed a $1.3bn obesity-focused research deal with Nimbus.</p>
<div class="lb-trans"><p>除了细胞和基因治疗，礼来在 2026 年迄今为止在并购舞台上是最活跃的大型制药公司。1 月，该公司收购了炎症专科公司 Ventyx，交易金额为 12 亿美元，并与 Nimbus 签署了一项针对肥胖的研究协议，金额为 13 亿美元。</p>
</div><p><em>Cell &amp; Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva</em>.</p>
<div class="lb-trans"><p><em>Pharmaceutical Technology 上的细胞与基因治疗报道由 Cytiva 支持。</em></p>
</div><p><em>Editorial content is independently produced and follows the</em> highest standards <em>of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.</em></p>
<div class="lb-trans"><p><em>编辑内容独立制作，并遵循_最高标准_的新闻诚信。主题赞助商不参与编辑内容的创作。</em></p>
</div>

Eli Lilly outlays $1.12bn for hearing loss gene therapy partnership

Pharmaceutical Technology

生物科技 ETF - VanEck Vectors

2 倍做多 LLY ETF - Defiance

Invesco Nasdaq Biotechnology ETF

2 倍做多 LLY ETF - Direxion

医药突破 ETF - ALPS

基因改革 ETF - ARK

标普全球医疗股指数 ETF - iShares

纳斯达克生物科技指数 ETF - iShares Nasdaq

医疗业 ETF - Vanguard

礼来

美国制药 ETF - iShares

礼来公司斥资 11.2 亿美元用于听力损失基因治疗的合作伙伴关系